Bryostatin 1

Category	Human immunodeficiency Virus (HIV)
CAS	83314-01-6
Description	Bryostatin 1, a structurally unique macrolactone marine natural product, is a protein kinase C (PKC) activator that binds with high affinity (Ki = 1.35 nM). Bryostatin 1 fails to mimic many effects caused by PMA and actually blocks some PMA-induced response in a variety of cells and tissues. Animal tests have shown bryostatin 1 may alleviate brain damage after a stroke.

Quotation Now

Product Information

Synonyms	Bryostatin-1; Bryostatin1; NSC-339555; NSC 339555; NSC339555; AC1L8WCW
IUPAC Name	[(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate
Molecular Weight	905.04
Molecular Formula	C47H68O17
Canonical SMILES	CCCC=CC=CC(=O)OC1C(=CC(=O)OC)CC2CC(OC(=O)CC(CC3CC(C(C(O3)(CC4CC(=CC(=O)OC)CC(O4)C=CC(C1(O2)O)(C)C)O)(C)C)OC(=O)C)O)C(C)O
InChI	InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3
InChIKey	MJQUEDHRCUIRLF-UHFFFAOYSA-N
Boiling Point	954.7°C at 760 mmHg
Flash Point	270.0±27.8 °C
Purity	≥99%
Density	1.27 g/cm3
Solubility	Soluble in DMSO, ethanol
Appearance	White lyophilised Solid
Application	Adjuvants, Immunologic
Storage	Store at -20°C
Complexity	1830
Exact Mass	904.44565070
Index Of Refraction	1.565
In Vitro	Bryostatin 1 (1μM; 5 minutes; HT22 cells) treatment successfully recruited Munc13-1 from the cell sol to the plasma membrane. The effect of Bryostatin 1 on other Munc13 family members ubMunc13-2 and bMunc13-2 is similar to the translocation effect of Munc13-1. Bryostatin 1 can also affect the immune system by modulating dendritic cells (DCs) through the MyD88-independent pathway through toll-like receptor 4 (TLR4), which promotes CD4+ T-assisted (Th) lymphocytes to differentiate into Th2 and Th1 effector cells by inducing a type 2 phenotype.
In Vivo	Bryostatin 1 (30μg/kg; Intraperitoneal injection; 3d per week; Lasts 2 weeks; C57BL/6J mice) treatment eliminates the occurrence of EAE.
PSA	240.11000
Target	PKC; HIV
Vapor Pressure	0.0±0.6 mmHg at 25°C
XLogP3-AA	4